US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.85

+0.49321.29%

Post-market: 38.81-0.0441-0.11%19:30 EDT

Volume:41.81K

Turnover:1.63M

Market Cap:356.29M

PE:- -

High:38.97

Open:38.51

Low:38.51

Close:38.36

52wk High:39.80

52wk Low:30.66

Shares:9.17M

Float Shares:9.17M

Volume Ratio:1.13

T/O Rate:0.46%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Wendy’s (WEN) Short Squeeze Has Cooled, but It’s Not Dead

Clas Ohlson posts double-digit summer sales growth but flags currency hedging headwinds

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Press Release: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Oriole Seals Senala JV with Managem as US$2m Drill Campaign Nears

Press Release: Oryzon Raises EUR12 Million and Signs a Financing Agreement with Cofides to Strengthen Its Balance Sheet and Accelerate Its Clinical Programs

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/ORR/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8541,"timestamp":1789156800000,"preClose":38.3609,"halted":0,"volume":41810,"hourTrading":{"tag":"盘后","latestPrice":38.81,"preClose":38.8541,"latestTime":"19:30 EDT","volume":120,"amount":4657.8846,"timestamp":1789169407285,"change":-0.0441,"changeRate":-0.001135,"amplitude":0},"delay":0,"changeRate":0.012856841210711992,"floatShares":9170000,"shares":9170000,"eps":0,"marketStatus":"Market Closed","change":0.4932,"latestTime":"09-11 16:00:00 EDT","open":38.51,"high":38.97,"low":38.51,"amount":1625557.7484000002,"amplitude":0.011991,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":38.3609,"sharesOutstanding":12900000,"nav":38.64,"aum":354328800,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":38.67,"preClose":38.3609,"latestTime":"09:28 EDT","volume":37,"amount":1427.6000820000002,"timestamp":1789133333850,"change":0.3091,"changeRate":0.008058,"amplitude":0.004171},"postHourTrading":{"tag":"盘后","latestPrice":38.81,"preClose":38.8541,"latestTime":"19:30 EDT","volume":120,"amount":4657.8846,"timestamp":1789169407285,"change":-0.0441,"changeRate":-0.001135,"amplitude":0},"volumeRatio":1.1316516036137798,"impliedVol":0.1515,"impliedVolPercentile":0.5029},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9170000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1316516036137798,"shares":9170000,"dividePrice":0,"high":38.97,"amplitude":0.011991,"preClose":38.3609,"low":38.51,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8541,"eps":0,"divideRate":0,"volume":41810,"delay":0,"ttmEps":0,"open":38.51,"prevYearClose":34.16,"prevWeekClose":39.1863,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":39.1754,"twentyDayClose":38.57,"sixtyDayClose":36.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652001290","title":"Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2652001290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652001290?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:30","pubTimestamp":1784547000,"startTime":"0","endTime":"0","summary":"Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4161","BK4124","SMP","BK4121","LAB","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652715280","title":"Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652715280","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652715280?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:15","pubTimestamp":1784319300,"startTime":"0","endTime":"0","summary":"Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July  17, 2026 (GLOBE NEWSWIRE) -- ZentalisPharmaceuticals, Inc. (Nasdaq: ZNTL), a cl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329282/0/en/Zentalis-Pharmaceuticals-to-Present-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PROC","BK4007","BK4195","EPV","PFS","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652400155","title":"Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400155","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652400155?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:15","pubTimestamp":1784286900,"startTime":"0","endTime":"0","summary":"Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329028/0/en/Evaxion-to-present-three-year-clinical-efficacy-data-for-personalized-cancer-vaccine-EVX-01-at-the-ESMO-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVX","ORR","VTHR","BK4139","AGIX","CHAT","AIPO","QTOC","EVAX","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105706","title":"InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105706","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105706?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:23","pubTimestamp":1784028180,"startTime":"0","endTime":"0","summary":"BEIJING, July  14, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that Signal Transduction and Targeted Therapy (STTT), a Nature Portfolio journal, published a pa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326726/0/en/InnoCare-Announces-Publication-in-STTT-IF-81-2-of-Phase-3-Results-Showing-Orelabrutinib-Significantly-Prolonged-Progression-Free-Survival-in-Treatment-Na%C3%AFve-CLL-SLL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","HR","PFS","BK4203","SRET","BK4225","CR","ORR","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111495","title":"Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111495","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111495?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944000,"startTime":"0","endTime":"0","summary":"INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326130/0/en/Immutep-Provides-Clinical-Update-in-1st-line-NSCLC-Positive-Mature-Overall-Survival-Data-from-INSIGHT-003-and-Update-from-TACTI-004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU2265009873.SGD","ORR","BK4198","ALC","LU1804176565.USD","BK4139","INAQU","IMMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607424","title":"Wendy’s (WEN) Short Squeeze Has Cooled, but It’s Not Dead","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649607424?lang=en_us&edition=fundamental","pubTime":"2026-07-07 15:38","pubTimestamp":1783409880,"startTime":"0","endTime":"0","summary":"Wendy’s ($WEN) short squeeze has cooled, but it is not dead. The fast-food chain’s shares have suddenly become one of the more interesting short-te...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/wendys-wen-short-squeeze-has-cooled-but-its-not-dead?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/wendys-wen-short-squeeze-has-cooled-but-its-not-dead?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LSEQ","FFLS","ORR","EVNT","HDGE","BERZ","BK4209","FTLS","DWSH","BK4547","CLSE","LBAY","SHRT","WEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649709609","title":"Clas Ohlson posts double-digit summer sales growth but flags currency hedging headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2649709609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649709609?lang=en_us&edition=fundamental","pubTime":"2026-07-07 13:33","pubTimestamp":1783402388,"startTime":"0","endTime":"0","summary":"Clas Ohlson AB ( ($SE:CLAS.B) ) just unveiled an announcement. Clas Ohlson reported a strong start to the summer trading period, with June net sale...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clas-ohlson-posts-double-digit-summer-sales-growth-but-flags-currency-hedging-headwinds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clas-ohlson-posts-double-digit-summer-sales-growth-but-flags-currency-hedging-headwinds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBFG","PYLD","FARX","ILOW","IQDY","LEXI","BUFI","WBND","IMAR","IPPP","PICB","HFSI","YJUN","DGCB","TOAK","INEQ","HEFA","TPLS","QINT","GHMS","FTRB","ADFI","PIEQ","SFGV","NUDM","IQDG","IOCT","HTRB","GTO","ISEP","ORR","ISHG","RTRE","YDEC","EFZ","QEFA","AGGS","DXIV","FTBD","DWMF","HDMV","DUKH","TOK","SCZ","BUFY","HAWX","DBEZ","GTR","IBUF","IFEB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649675228","title":"Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2649675228","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649675228?lang=en_us&edition=fundamental","pubTime":"2026-07-07 01:59","pubTimestamp":1783360740,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/06/3322680/0/en/Genmab-Announces-TEPKINLY-epcoritamab-in-Combination-with-Lenalidomide-and-Rituximab-is-Approved-by-the-European-Commission-for-the-Treatment-of-Relapsed-or-Refractory-Follicular-L.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","CRS","BK4201","XAR","LU2065731478.USD","PYZ","APHP","BK4006","EPV","ORR","PFS","IE00B66KJ199.SGD","BK4211","IE0031619046.USD","CR","BK4195","IE00B19Z4B17.USD","BK4187","BK4161","BK4108","IE00B7SZL793.SGD","EC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649062991","title":"Press Release: Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2649062991","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649062991?lang=en_us&edition=fundamental","pubTime":"2026-07-06 20:00","pubTimestamp":1783339200,"startTime":"0","endTime":"0","summary":"NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\"), a clinical-stage company focused on developing promising new therapi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4022","BK4139","BK4080","BK4232","NETL","CRBP","BK4231","R","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649092645","title":"Oriole Seals Senala JV with Managem as US$2m Drill Campaign Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2649092645","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649092645?lang=en_us&edition=fundamental","pubTime":"2026-07-06 14:18","pubTimestamp":1783318721,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Oriole Resources PLC ( ($GB:ORR) ). Oriole Resources PLC has finalized a joint venture agreement with Managem s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-seals-senala-jv-with-managem-as-us2m-drill-campaign-nears?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-seals-senala-jv-with-managem-as-us2m-drill-campaign-nears?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648545938","title":"Press Release: Oryzon Raises EUR12 Million and Signs a Financing Agreement with Cofides to Strengthen Its Balance Sheet and Accelerate Its Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2648545938","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648545938?lang=en_us&edition=fundamental","pubTime":"2026-07-01 21:08","pubTimestamp":1782911280,"startTime":"0","endTime":"0","summary":"-- Priced at EUR2.70 per share, representing a 14.15% discount on the. five-day VWAP and a 12.68% discount to the June 30 closing price. -- The transaction has been structured as a capital increase without the. -- Proceeds will be used to advance the Company's clinical development. -- Cover general and administrative expenses and financial obligations.Dr. Carlos Buesa, Chief Executive Officer of Oryzon, said: \"This funding comes at a particularly important time for Oryzon and strengthens our ability to execute our clinical strategy with greater confidence. The progress of our acute myeloid leukemia program is attracting increasing attention across the international oncology ecosystem, including among leading experts, pharmaceutical companies, and specialized investors. With this support, we gain financial flexibility to accelerate our priority programs while continuing to explore strategic opportunities that can maximize the value of our platform.\"Agreement with the Social Impact Fund ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","BK4135","BK4156","ORR","CNS","BK4090","CMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646870966","title":"MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2646870966","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646870966?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:08","pubTimestamp":1782389280,"startTime":"0","endTime":"0","summary":"Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June  25, 2026  (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317503/0/en/MAIA-Biotechnology-Completes-International-Enrollment-in-Part-C-of-Phase-2-THIO-101-Expansion-Trial-in-Third-Line-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","LU0210528500.USD","CPI","BK4585","BK4107","LU0053666078.USD","BK4139","L","MAIA","BK4588","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646484290","title":"HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2646484290","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646484290?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:00","pubTimestamp":1782345600,"startTime":"0","endTime":"0","summary":"— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control — — Fanregratinib holds promise as a new treatment option for pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317235/0/en/HUTCHMED-Highlights-Pivotal-Phase-II-Data-for-Fanregratinib-in-Intrahepatic-Cholangiocarcinoma-Presented-at-ESMO-Gastrointestinal-Cancers-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK1191","00013","BK1587","ORR","PFS","BK4195","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643548277","title":"Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76","url":"https://stock-news.laohu8.com/highlight/detail?id=2643548277","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643548277?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:30","pubTimestamp":1781519400,"startTime":"0","endTime":"0","summary":"29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer (“PROC”) who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome (“CRS”)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3311621/0/en/Context-Therapeutics-Announces-Positive-Interim-Efficacy-and-Safety-Results-from-Ongoing-Phase-1-Clinical-Trial-for-CTIM-76.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","ORR","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228204","title":"Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228204?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:30","pubTimestamp":1781479800,"startTime":"0","endTime":"0","summary":"Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, Ch","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311475/0/en/Ascentage-Pharma-Presents-Multiple-Clinical-Updates-at-EHA2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","AAPG","ORR","BK4139","BK4195","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643246367","title":"Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2643246367","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643246367?lang=en_us&edition=fundamental","pubTime":"2026-06-14 15:15","pubTimestamp":1781421300,"startTime":"0","endTime":"0","summary":"Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311435/0/en/Legend-Biotech-Establishes-Clinical-Proof-of-Concept-for-LB2501-a-Potential-First-in-Class-In-Vivo-CD19-CD20-Dual-Targeting-CAR-T-in-Relapsed-Refractory-B-Cell-Non-Hodgkin-Lymphoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4505","BK4161","BK4588","IRR","XBI","IE00B66KJ199.SGD","BK4022","IE00B19Z4B17.USD","BK4139","BK4187","BK4230","CAR","ORR","BK4585","LU0963586101.USD","CRS","LEGN","IE0031619046.USD","CR","IE00B7SZL793.SGD","LU2065731478.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217815","title":"Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217815","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217815?lang=en_us&edition=fundamental","pubTime":"2026-06-14 00:45","pubTimestamp":1781369100,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly di","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/13/3311409/0/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Ly.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","IE00B19Z4B17.USD","ORR","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4161","BK4211","BK4195","IE0031619046.USD","PFS","LU2065731478.USD","LU0963586101.USD","BK4006","BK4187","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238199","title":"Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating  Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238199?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:45","pubTimestamp":1781189100,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lena","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310630/0/en/Genmab-Presents-EPCORE-FL-1-Subgroup-Data-Demonstrating-Consistent-Efficacy-and-Safety-Results-for-Epcoritamab-in-Combination-with-Rituximab-and-Lenalidomide-R2-Across-Relapsed-or-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","HR","BK4161","CR","BK4225","PFS","ORR","BK4211","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282822","title":"Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282822","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282822?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179200,"startTime":"0","endTime":"0","summary":"-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-nave patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case stu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310377/0/en/Caribou-Biosciences-Reports-Dose-Escalation-Durability-Data-for-CB-011-at-the-2026-European-Hematology-Association-EHA-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CAR","BK4006","LU1506573853.SGD","BK4559","ALT","BK4187","BK4139","BK4022","IE00B66KJ199.SGD","IE0031619046.USD","IE00B19Z4B17.USD","LD","LU0314106906.USD","BK4107","ORR","BK4539","LU1878469433.USD","CRBU","IE00B7SZL793.SGD","BK4599","LU0963586101.USD","BK4588","BK4230","LU0417517546.SGD","LU0256863811.USD","LU2065731478.USD","CRS","EPV","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289420","title":"Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289420","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289420?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:03","pubTimestamp":1781175780,"startTime":"0","endTime":"0","summary":"–Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – –Ph 1 trial of revumenib with int","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310342/0/en/Syndax-Showcases-Revuforj-revumenib-Clinical-Activity-in-Multiple-Acute-Leukemia-Subtypes-and-Settings-at-EHA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","BK4500","ECG","LU0566484027.USD","BK4161","BK4588","ORR","BK4585","LU1559883803.SGD","LU1699723380.USD","BK4129","ALL","HSCT","SAVE","BK4008","LU1571399168.USD","LU0985320562.USD","BK4533","CR","LU2355687059.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":129,"code":"91000000","status":"200"}]}}